Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Metformin

Journal articles and book chapters

21-06-2018 | Pathophysiology | Review | Article

The gut microbiome as a target for the treatment of type 2 diabetes

Aydin Ö, Nieuwdorp M, Gerdes V. Curr Diab Rep 2018; 18: 55. doi: 10.1007/s11892-018-1020-6

21-06-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

16-06-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

15-06-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

14-06-2018 | Pioglitazone | Article

Pioglitazone use and risk of bladder cancer: A systematic literature review and meta-analysis of observational studies

Mehtälä J et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0360-4

12-06-2018 | Empagliflozin | Article

Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

09-06-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

08-06-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

06-06-2018 | Lifestyle interventions | Article

A peer-support lifestyle intervention for preventing type 2 diabetes in India: A cluster-randomized controlled trial of the Kerala Diabetes Prevention Program

Thankappan KR et al. PLoS Med 2018; 15: e1002575. doi: 10.1371/journal.pmed.1002575

05-06-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

01-06-2018 | DPP-4 inhibitors | Article

Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

28-05-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

25-05-2018 | Oral combination medications | Article

Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

22-05-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9

19-05-2018 | Risk factors | Review | Article

Prioritising risk factors for type 2 diabetes: Causal inference through genetic approaches

Wittemans LBL, Lotta LA, Langenberg C. Curr Diab Rep 2018; 18: 40. doi: 10.1007/s11892-018-1009-1

19-05-2018 | Liraglutide (T2DM) | Article

Retrospective analysis of an insulin-to-liraglutide switch in patients with type 2 diabetes mellitus

Introduction: Insulin and the GLP-1 receptor agonist liraglutide are both effective in reaching glycemic targets. The efficacy of an insulin-to-liraglutide switch in an obese population with concurrent use of sulfonylurea and metformin is unknown. We assessed the efficacy and determinants of success of an insulin-to-liraglutide switch in these patients.

18-05-2018 | Type 2 diabetes | Review | Article

Combination glucose-lowering therapy plans in T2DM: Case-based considerations

Blonde L, Dipp S, Cadena D. Adv Ther 2018. doi: 10.1007/s12325-018-0694-0

18-05-2018 | Gestational diabetes | Review | Article

Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes

Yeung RO et al. Rev Endocr Metab Disord 2018. doi: 10.1007/s11154-018-9446-3

14-05-2018 | Insulin glargine | Article

Characteristics of insulin-naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: A meta-analysis of individual participant data from 3 randomized clinical trials

Cummings MH et al. Clin Diabetes Endocrinol 2018; 4: 10. doi: 10.1186/s40842-018-0059-2

09-05-2018 | Liraglutide (T2DM) | Article

Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years

Li Q et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0432-2

Next Previous